Ginsenoside Rk3
Ginsenoside Rk3 is often used as a major ingredient of the compound preparation for ischemic heart diseases, it could have a role in treating inflammatory diseases. Ginsenoside Rk3 significantly inhibits TNF-α-induced NF-κB transcriptional activity, with an IC50 of 14.24±1.30 μM in HepG2 cells.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
J Nat Prod.2019, 82(4):1002-1008
Evid Based Complement Alternat Med.2018, 2018:4580627
Molecules.2022, 27(7):2360.
Pharmaceuticals (Basel).2024, 17(4):462.
Biochem Pharmacol. 2023, 210:115463.
Applied Biological Chemistry2020, 63:33(2020)
Life Sci.2018, 209:498-506
Archives of Biological sciences2022, 00:21-21
J Pharm Anal.2016, 6(6):363-373
Institute of Food Science & Technology2021, 56(11).
Related and Featured Products
Evid Based Complement Alternat Med. 2013;2013:690190.
Ginsenoside RK3 Prevents Hypoxia-Reoxygenation Induced Apoptosis in H9c2 Cardiomyocytes via AKT and MAPK Pathway.[Pubmed:
23935671 ]
Cardiac hypertrophy is a thickening of the heart muscle that is associated with cardiovascular diseases such as hypertension and myocardial infarction. It occurs initially as an adaptive process against increased workloads and often leads to sudden arrhythmic deaths. Studies suggest that the lethal arrhythmia is attributed to hypertrophy-induced destabilization of cardiac electrical activity, especially the prolongation of the action potential. The reduced activity of Ito is demonstrated to be responsible for the ionic mechanism of prolonged action potential duration and arrhythmogeneity. Isosteviol (STV), a derivative of stevioside, plays a protective role in a variety of stress-induced cardiac diseases.
METHODS AND RESULTS:
Here we report effects of STV on rat ISO-induced hypertrophic cardiomyocytes. STV alleviated ISO-induced hypertrophy of cardiomyocytes by decreasing cell area of hypertrophied cardiomyocytes. STV application prevented the prolongation of action potential which was prominent in hypertrophied cells.
CONCLUSIONS:
The decrease and increase of current densities for Ito and ICaL observed in hypertrophied myocytes were both prevented by STV application. In addition, the results of qRT-PCR suggested that the changes of electrophysiological activity of Ito and ICaL are correlated to the alterations of the mRNA transcription level.
Food Funct . 2017 Oct 18;8(10):3723-3736.
Anticancer effects of ginsenoside Rk3 on non-small cell lung cancer cells: in vitro and in vivo[Pubmed:
28949353]
Abstract
Ginsenoside Rk3 (Rk3) is present in the roots of processed Panax notoginseng herbs and it exerts anti-platelet aggregation, pro-immunogenic and cardioprotective effects. However, little is known regarding the anticancer activities of this compound, especially in lung cancer. This study was designed to investigate the anticancer effects of Rk3 on non-small cell lung cancer (NSCLC) cells and in an H460 xenograft tumor model. Our results showed that Rk3 reduced cell viability, inhibited both cell proliferation and colony formation, and induced G1 phase cell cycle arrest by downregulating the expression of cyclin D1 and CDK4 and upregulating the expression of P21. Rk3 also induced apoptosis in a concentration-dependent manner in H460 and A549 cells by Annexin V/PI staining, TUNEL assay and JC-1 staining, resulting in a change in the nuclear morphology. Moreover, Rk3 induced the activation of caspase-8, -9, and -3, promoted changes in mitochondrial membrane potential, decreased the expression of Bcl-2, increased the expression of Bax, and caused the release of cytochrome c, which indicated that the apoptosis-inducing effects of Rk3 were triggered via death receptor-mediated mitochondria-dependent pathways. Furthermore, Rk3 significantly inhibited the growth of H460 xenograft tumors without an obvious effect on the body weight of the treated mice. Histological analysis indicated that Rk3 inhibited tumor growth by altering the proliferation and morphology of tumor cells. In addition, we confirmed that Rk3 inhibited angiogenesis via CD34 staining and chick embryo chorioallantoic membrane (CAM) assay in vivo. Taken together, our findings revealed not only the anticancer effect of Rk3 on NSCLC cells but also a new promising therapeutic agent for human NSCLC.
Biol Pharm Bull. 2011;34(6):898-900.
Anti-complementary ginsenosides isolated from processed ginseng.[Pubmed:
21628891]
METHODS AND RESULTS:
As part of an ongoing search for immunomodulatory components aimed at the anti-complementary effect, ginsenosides isolated from processed ginseng were found to have inhibitory activity on complement activation through classical pathways. Activity-guided fractionation was used to isolate four ginsenosides, namely ginsenoside Rg₆, F₄, Rk₃, and Rh₄. Ginsenoside Rk₃ and Rh₄ had a 3 fold higher inhibition activity than rosmarinic acid which was used as a positive control while ginsenoside Rg₆ and F₄ showed only mild effects similar to that of the positive control.
CONCLUSIONS:
The results suggest that the activity of the corresponding ginsenosides may be increased by the glycosyl moiety at the C₆ position rather than the double bond conformation at C₂₀, and ginsenoside Rk₃ and Rh₄ could have a role in treating inflammatory diseases.
20-O-Glucoginsenoside Rf
Catalog No: CFN95036
CAS No: 68406-27-9
Price: $318/5mg
Iristectorin A
Catalog No: CFN95037
CAS No: 37744-61-9
Price: $318/20mg
5-Hydroxy-7-(4'-hydroxy-3'-methoxyphenyl)-1-phenyl-3-heptanone (DHPA)
Catalog No: CFN95135
CAS No: 79559-61-8
Price: $268/20mg
3,7,25-Trihydroxycucurbita-5,23-dien-19-al
Catalog No: CFN95150
CAS No: 85372-65-2
Price: $318/5mg
Momordicine V
Catalog No: CFN95164
CAS No: 1012315-36-4
Price: $463/5mg
(3S,5S,E)-1,7-Diphenylhept-1-ene-3,5-diol
Catalog No: CFN95195
CAS No: 87095-75-8
Price: $318/5mg
3-Hydroxy-4',5-dimethoxystilbene
Catalog No: CFN95199
CAS No: 58436-29-6
Price: $318/10mg
Eucomic acid
Catalog No: CFN95364
CAS No: 42151-32-6
Price: $368/5mg
3'-Hydroxy-5,7,4',5'-Tetramethoxyflavone
Catalog No: CFN95397
CAS No: 29976-51-0
Price: $318/5mg
Senkyunolide N
Catalog No: CFN95449
CAS No: 140694-58-2
Price: $318/10mg